JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(3):E1-E5 | DOI: 10.36290/csf.2025.024

ADME Profile Calculation and Drug Similarity Study of New 1,2,4-Triazole Derivatives Containing 2-Bromo-5-Methoxyphenyl Radical

Mykola Skoryi1, Roman Shcherbyna1, Sergii Kulish1, Volodymyr Salionov2, Oleksandra Cherchesova3
1 Department of Toxicological and Inorganic Chemistry, Faculty of Pharmacy, Zaporizhzhia Medical and Pharmaceutical University, Zaporizhzhya, Ukraine
2 Department of Biological Chemistry, Faculty of Pharmacy, Zaporizhzhia Medical and Pharmaceutical University, Zaporizhzhya, Ukraine
3 Professional Medical and Pharmaceutical College of PJSC „Higher Education Institution“ MAUP, Kyiv, Ukraine

Introduction: Evaluating ADME (absorption, distribution, metabolism, excretion) profiles is critical in drug development to ensure bioavailability, efficacy, and safety. 1,2,4-Triazole derivatives, particularly those with a 2-bromo-5-methoxyphenyl radical, are promising due to their broad biological activities, yet their pharmacokinetic properties are insufficiently studied. The objective of this study was to predict the ADME characteristics and drug-likeness of these compounds to identify candidates with optimal pharmacokinetic potential for therapeutic applications.

Objectives: This study aimed to assess the ADME profiles of new 1,2,4-triazole derivatives incorporating a 2-bromo-5-methoxyphenyl fragment using in silico methods and evaluate their compliance with drug-likeness criteria, such as Lipinski’s Rule of 5, for potential pharmaceutical development.

Methods: A series of 28 derivatives, including 5-(2-bromo-5-methoxyphenyl)-4-R-1,2,4-triazole-3-thiols (3a–3d), thioacetic acids (4a–4d), and esters (5a–5t), were analyzed via the Molinspiration Property Calculator. Key parameters assessed were lipophilicity (miLogP), polar surface area (TPSA), molecular weight (MW), hydrogen bond donors (nOHNH) and acceptors (nON), rotatable bonds (nrotb), and Lipinski rule violations (nviolations).

Results: Thiol derivatives (3a–3d) showed moderate lipophilicity (miLogP 3.02-3.33) and TPSA (39.95–50.81 Ų), suggesting good permeability. Thioacetic acids (4a–4d) had higher TPSA (77.25–88.11 Ų) and lower miLogP (2.46–3.81), indicating enhanced solubility but reduced permeability. Esters (5a–5t) varied widely in lipophilicity (miLogP 3.08–5.86), with three compounds (5l, 5p, 5t) exceeding Lipinski’s miLogP limit (> 5). Most compounds complied with Lipinski’s Rule, with MW ranging from 286.15–476.40 g/mol and nrotb from 2–10.

Conclusion: Structural modifications significantly influenced ADME profiles, with thiols and thioacetic acids showing favorable drug-like properties. High-lipophilicity esters may require optimization. These findings support the potential of these triazole derivatives as drug candidates, warranting further pharmacological studies.

Keywords: 1,2,4-triazole, ADME, in silico, drug-likeness, pharmacokinetics, 2-bromo-5-methoxyphenyl.

Accepted: September 15, 2025; Published: October 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skoryi M, Shcherbyna R, Kulish S, Salionov V, Cherchesova O. ADME Profile Calculation and Drug Similarity Study of New 1,2,4-Triazole Derivatives Containing 2-Bromo-5-Methoxyphenyl Radical. Čes. slov. farm. 2025;74(3):E1-5. doi: 10.36290/csf.2025.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 40 CZK

    References

    1. Ekins S, Lane TR, Urbina F, Puhl AC. In silico ADME/tox comes of age: twenty years later. Xenobiotica. 2024;54(7):352-358. Go to original source... Go to PubMed...
    2. Maver T, Vihar B, Maver U. A narrative review of ADME testing platforms. Acta Med Biotech. 2024;17(2):9-17. Go to original source...
    3. Lohit N, Singh AK, Kumar A, Singh H, Yadav JP, Singh K, et al. Description and in silico ADME studies of US-FDA approved drugs or drugs under clinical trial which violate the Lipinski's Rule of 5. Lett Drug Des Discov. 2024;21(8):1334-1358. Go to original source...
    4. Johnson DB, Singh G, Sharma D, Natarajan V, Lakshmi KNVC, Dhakar RC, et al. Exploring computational advancements in ADME: essential insights for drug disposition. Chin J Appl Physiol. 2024;40:e20240033. Go to original source... Go to PubMed...
    5. Paggi JM, Pandit A, Dror RO. The art and science of molecular docking. Annu Rev Biochem. 2024;93:261-284. Go to original source... Go to PubMed...
    6. De P, Kar S, Ambure P, Roy K. Prediction reliability of QSAR models: an overview of various validation tools. Arch Toxicol. 2022;96(5):1279-95. Go to original source... Go to PubMed...
    7. Tiwari S, Nagarajan K, Gupta A. SwissADME: an in silico ADME examination tool. In: Alam S, Gupta A, editors. Computational biology in drug discovery. Boca Raton (FL): CRC Press; 2024. p. 415-424.
    8. Shcherbyna R, Pruhlo Y, Duchenko M, Kulagina M, Kudria V, Vashchuk V. Evaluation of antioxidant activity of 1, 2, 4-triazole derivatives with morpholine moiety. Hacettepe Univ J Fac Pharm. 2022;42(2):73-82. Go to original source...
    9. Shcherbyna R, Panasenko O, Polonets O, Nedorezaniuk N, Duchenko M. Synthesis, antimicrobial and antifungal activity of ylidenehydrazides of 2-((4-R-5-R1-4H-1,2,4-triazol-3-yl)thio)acetaldehydes. J Fac Pharm Ankara Univ. 2021;45(3):504-514. Go to original source...
    10. Shcherbyna R. An investigation of the pharmacokinetics and potential metabolites of potassium 2-((4-amino-5-(morfolinometyl)-4H-1,2,4-triazol-3-yl)thio) acetate on rats. J Fac Pharm Ankara Univ. 2020;44(2):233-241. Go to original source...
    11. Usenko DL, Varynskyi BO, Kaplaushenko AH, Safonov AA, Panasenko OI, Morozova LP, et al. The research of pharmacokinetic parameters and metabolism of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetate for use in military and civilian medicine. Ukr J Mil Med. 2024;5(4):159-167. Go to original source...
    12. Sameliuk Y, Kaplaushenko A, Diakova F, Ostretsova L, Nedorezaniuk N, Gutyj B. Prospects for the search for new biologically active compounds among the derivatives of the heterocyclic system of 1,2,4-triazole. Hacettepe Univ J Fac Pharm. 2022;42(3):175-186. Go to original source...
    13. Hotsulia AS, Brytanova TS, Fedotov SO, Ubogov SG, Pidlisnyi OV, Yaroshenko IV. The pharmacological potential of 1-alkyl derivatives of 4-((4-nitrobenzylidene)amino)-1,2,4-triazole. Ukr J Mil Med. 2024;5(3):85-94. Go to original source...
    14. Zvenihorodska T, Hotsulia A, Kravchenko S, Fedotov S, Kyrychko B. Synthesis and antimicrobial action of 1,2,4-triazole derivatives containing theophylline and 1,3,4-thiadiazole fragments in their structure. Afr J Biomed Res. 2021;24(1):159-163.
    15. Safonov A, Demianenko D, Vashchyk Y, Larianovska Y, Lytkin D, Shcherbyna R, et al. Histological study of a corrective influence of sodium 2-((4-amino-5-(thiophen-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio) acetate on the state of rats liver under conditions of acute immobilization stress. J Fac Pharm Ankara Univ. 2022;46(2):330-341. Go to original source...
    16. Isaicheva K, Kaplaushenko A, Sameliuk Y. Synthesis, determination of physico-chemical parameters, structure confirmation, and antioxidant activity of compounds based on 3,5-bis(5-mercapto-4-R-4Н-1,2,4-triazole-3-yl)phenol. Sci Rise Pharm Sci. 2024;51(5):63-70. Go to original source...
    17. Zafar W, Sumrra SH, Chohan ZH. A review: pharmacological aspects of metal based 1,2,4-triazole derived Schiff bases. Eur J Med Chem. 2021;222:113602. Go to original source... Go to PubMed...
    18. Kaur R, Ranjan Dwivedi A, Kumar B, Kumar V. Recent developments on 1,2,4-triazole nucleus in anticancer compounds: a review. Anticancer Agents Med Chem. 2016;16(4):465-489. Go to original source... Go to PubMed...
    19. Mohamed MS, Ibrahim NA, Gouda AM, Badr M, El-Sherief HAM. Design, synthesis and molecular docking of 1,2,4-triazole schiff base hybrids as tubulin, EGFR inhibitors and apoptosis-inducers. J Mol Struct. 2023;1286:135621. Go to original source...
    20. Sadeghian S, Emami L, Mojaddami A, Khabnadideh S, Faghih Z, Zomorodian K, et al. 1,2,4-Triazole derivatives as novel and potent antifungal agents: design, synthesis and biological evaluation. J Mol Struct. 2023;1271:134039. Go to original source...
    21. Kiran PVR, Waiker DK, Verma A, Saraf P, Bhardwaj B, Kumar H, et al. Design and development of benzyl piperazine linked 5-phenyl-1,2,4-triazole-3-thione conjugates as potential agents to combat Alzheimer's disease. Bioorg Chem. 2023;139:106749. Go to original source... Go to PubMed...
    22. Gitto R, Vittorio S, Bucolo F, Peña-Díaz S, Siracusa R, Cuzzocrea S, et al. Discovery of neuroprotective agents based on a 5-(4-pyridinyl)-1,2,4-triazole scaffold. ACS Chem Neurosci. 2022;13(5):583-591. Go to original source... Go to PubMed...
    23. Skoryi M, Shcherbyna R, Salionov V. Synthesis and biological potential of 1,2,4-triazole derivatives with a 2-bromo-5-methoxyphenyl fragment. In: Proceedings of the scientific conference. Zaporizhzhia: Zaporizhzhia State Medical and Pharmaceutical University; 2023. p. 162-164.
    24. Skoryi MP, Shcherbyna RO. QSAR prediction of toxicity for a new 1,2,4-triazole derivatives with 2-bromo-5-methoxyphenyl fragment. Curr Issues Pharm Med Sci Pract. 2024;17(3):226-230. Go to original source...
    25. Suganya M, Hemamalini M, Jose Kavitha S, Rajakannan V. In silico studies of molecular property and bioactivity of organic crystalline compounds using Molinspiration. Int Res J Eng Technol. 2020;7(2):519. [cited 2025 Apr 20]. Available from: https://www.irjet.net
    26. Mishra SS, Kumar N, Pandiya H, Singh HP, Sharma CS. In silico pharmacokinetic, bioactivity and toxicity study of some selected anti-anginal agents. Int J Appl Pharm Biol Res. 2017;2(4):57-60. [cited 2025 Apr 20]. Available from: http://www.ijapbr.com/

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.